Cipla Q3 PAT likely to grow 32% at Rs 307 cr

India's second largest pharma company by market cap Cipla is likely to report a profit after tax of Rs 307 crore in the October-December quarter of FY12, a massive growth of 32% as compared to Rs 232.7 crore in a year ago quarter.

EBITDA too is seen moving up by 35.5% to Rs 431 crore from Rs 318 crore year-on-year.

Operating profit margin is expected to be at 24% in the quarter ended December FY12 versus 20.5% in the corresponding quarter of last fiscal and 24.6% in the previous quarter.

Revenues are likely to go up by 14.2% to Rs 1,774 crore from Rs 1,554 crore YoY.

On quarter-on-quarter basis, revenues and profit after tax are expected to be flat.
 
Watch out for:

- Exports growth to be led by pick up in Indore SEZ, API & currency depreciation

- Average INR/USD rate for Cipla was Rs 51.12